Quetiapine probably leads to lower extrapyramidal effects compared with typical antipsychotics (moderate certainty).
BENZODIAZEPINES showed no clear difference in desired sedation ‐ ultra short term ‐ asleep at 12 hours compared with ANTIPSYCHOTICS (low certainty).
It is very uncertain whether BENZODIAZEPINES changes no clinically important response to treatment ‐ ultra short term (at… compared with ANTIPSYCHOTICS (very low certainty).
It is very uncertain whether BENZODIAZEPINES changes no clinically important response to treatment ‐ short term compared with ANTIPSYCHOTICS (very low certainty).
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to adverse effects (overall tolerability… compared with ANTIPSYCHOTICS (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ due to adverse events compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).
CLOZAPINE probably leads to lower relapse ‐ short term compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).